BioStock: Chordate enters 2022 with strong confidence

During 2021, Chordate Medical were able to ensure that several important pieces fell into place, such as the CE marking which allowed K.O.S to be marketed as a migraine treatment in the EU. Chordate is now looking forward to another eventful year that will include a list change to First North Growth Market and completion of the company’s migraine study. BioStock contacted CEO Anders Weilandt for a comment.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/chordate-enters-2022-with-strong-confidence/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se